Anticancer drugs: Double strike.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 716, doi. 10.1038/nrd1832
- By:
- Publication type:
- Article
Works matching IS 14741776 AND DT 2005 AND VI 4 AND IP 9
Results: 23
1
2
RNA interference: Knocked down for the count.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 717, doi. 10.1038/nrd1833
- By:
- Publication type:
- Article
3
Case History: The Discovery of Fluoxetine Hydrochloride (Prozac).
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 764, doi. 10.1038/nrd1821
- By:
- Publication type:
- Article
4
Can we Develop Neurally Acting Drugs for the Treatment of Migraine?
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 741, doi. 10.1038/nrd1822
- By:
- Publication type:
- Article
5
Automated synthesis of oligosaccharides as a basis for drug discovery.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 751, doi. 10.1038/nrd1823
- By:
- Publication type:
- Article
6
Opportunities and Challenges in Antiparasitic Drug Discovery.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 727, doi. 10.1038/nrd1824
- By:
- Publication type:
- Article
7
Model organisms: The ascent of mouse: advances in modelling human depression and anxiety.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 775, doi. 10.1038/nrd1825
- By:
- Publication type:
- Article
8
Outlook: directed development: catalysing a global biotech industry.
- Published in:
- 2005
- By:
- Publication type:
- review
9
From the analyst's couch: Wet age-related macular degeneration.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 711, doi. 10.1038/nrd1827
- By:
- Publication type:
- Article
10
Fresh from the pipeline: Exenatide.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 713, doi. 10.1038/nrd1828
- By:
- Publication type:
- Article
11
Patent primer: Maximizing exclusivity for drug products.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 709, doi. 10.1038/nrd1829
- By:
- Publication type:
- Article
12
Erratum: Anti-angiogenics steal the show.
- Published in:
- 2005
- Publication type:
- Correction Notice
13
HIV-1: Viral assembly inhibitors on the horizon.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 716, doi. 10.1038/nrd1834
- By:
- Publication type:
- Article
14
Paul L. Herrling.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 710, doi. 10.1038/nrd1836
- Publication type:
- Article
15
Europe fiddles while innovation burns.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 704, doi. 10.1038/nrd1838
- By:
- Publication type:
- Article
16
Tysabri risk causing headache for companies.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 703, doi. 10.1038/nrd1837
- By:
- Publication type:
- Article
17
Acquisitions not a cure for antiinfectives.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 704, doi. 10.1038/nrd1839
- By:
- Publication type:
- Article
18
News In Brief.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 706, doi. 10.1038/nrd1840
- Publication type:
- Article
19
Patentwatch: Baffled by claim construction.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 708, doi. 10.1038/nrd1841
- By:
- Publication type:
- Article
20
Patentwatch: 'Optional' ingredients anticipate.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 708, doi. 10.1038/nrd1842
- By:
- Publication type:
- Article
21
One world problem, one world solution?
- Published in:
- 2005
- Publication type:
- Editorial
22
In This Issue.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 9, p. 699, doi. 10.1038/nrd1844
- Publication type:
- Article
23
Erratum: The emerging field of lipidomics.
- Published in:
- 2005
- By:
- Publication type:
- Correction Notice